Remus Pharmaceuticals Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Remus Pharmaceuticals Ltd is ₹ 705.75 as of 05 May 15:30 . The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 .The P/E Ratio of Sanofi Consumer Healthcare India Ltd is 0 as of March 2024 . The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 .The Market Cap of Sanofi Consumer Healthcare India Ltd is ₹ 0 crore as of March 2024 . The revenue of Remus Pharmaceuticals Ltd for the Jun '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sanofi Consumer Healthcare India Ltd for the Jun '26 is ₹ 234.8 crore as compare to the Dec '25 revenue of ₹ 255.6 crore. This represent the decline of -8.14% The ebitda of Remus Pharmaceuticals Ltd for the Jun '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sanofi Consumer Healthcare India Ltd for the Jun '26 is ₹ 94.4 crore as compare to the Dec '25 ebitda of ₹ 94.4 crore. This represent the decline of 0% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 62.7 crore to ₹ 67.8 crore over 7 quarters. This represents a CAGR of 4.57% The Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 0 % on December 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 years .

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

About Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.

FAQs for the comparison of Remus Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd

Which company has a larger market capitalization, Remus Pharmaceuticals Ltd or Sanofi Consumer Healthcare India Ltd?

Market cap of Remus Pharmaceuticals Ltd is 831 Cr while Market cap of Sanofi Consumer Healthcare India Ltd is 10,577 Cr

What are the key factors driving the stock performance of Remus Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd?

The stock performance of Remus Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Remus Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd?

As of May 5, 2026, the Remus Pharmaceuticals Ltd stock price is INR ₹705.75. On the other hand, Sanofi Consumer Healthcare India Ltd stock price is INR ₹4592.6.

How do dividend payouts of Remus Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd compare?

To compare the dividend payouts of Remus Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.